BIOVENTUS INC. (BVS) Current Ratio
- Current ratio · latest quarter: Value 1.69×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.69× | Current assets / current liabilities. $257.53M ÷ $152.45M ≈ 1.69× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 257.53M USD | Assets, Current |
| Current obligations | 152.45M USD | Liabilities, Current |
| Cash and equivalents | 29.46M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 138.41M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 79.81M USD | Inventory, Net |
| Payables | 20.20M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 18.75M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $257.53M | $152.45M | $29.46M | (m) | $138.41M | $79.81M | $20.20M | $18.75M | 1.69× |
| 2026-03-28 | $249.81M | $148.09M | $35.85M | (m) | $120.53M | $83.19M | $24.05M | $18.75M | 1.69× |
| 2025-12-31 | $272.84M | $160.38M | $51.24M | (m) | $128.30M | $82.24M | $10.93M | $15.00M | 1.70× |
| 2025-09-27 | $280.90M | $161.75M | $42.16M | (m) | $130.40M | $96.27M | $26.65M | $11.25M | 1.74× |
| 2025-06-28 | $275.20M | $185.68M | $32.91M | (m) | $132.37M | $96.47M | $24.25M | $43.36M | 1.48× |
| 2025-03-29 | $249.37M | $174.75M | $22.80M | (m) | $118.08M | $94.05M | $19.20M | $37.34M | 1.43× |
| 2024-12-31 | $275.61M | $210.40M | $41.58M | (m) | $127.39M | $92.47M | $23.69M | $27.34M | 1.31× |
| 2024-09-28 | $298.69M | $211.49M | $43.07M | (m) | $121.92M | $90.03M | $16.85M | $38.57M | 1.41× |
| 2024-06-29 | $308.88M | $231.46M | $31.99M | (m) | $137.31M | $87.61M | $24.44M | $38.57M | 1.33× |
| 2024-03-30 | $265.90M | $173.32M | $25.17M | (m) | $125.54M | $97.00M | $19.10M | $35.81M | 1.53× |
| 2023-12-31 | $268.00M | $175.50M | $36.96M | (m) | $122.79M | $91.33M | $23.04M | $27.85M | 1.53× |
| 2023-09-30 | $249.45M | $160.84M | $26.83M | (m) | $112.90M | $97.56M | $17.64M | $19.58M | 1.55× |
| 2023-07-01 | $260.64M | $179.10M | $29.39M | (m) | $119.64M | $96.28M | $41.36M | $11.32M | 1.46× |
| 2023-04-01 | $308.66M | $196.06M | $47.10M | (m) | $118.54M | $87.95M | $32.83M | $41.32M | 1.57× |
| 2022-12-31 | $272.57M | $304.02M | $30.19M | (m) | $136.29M | $84.77M | $36.70M | $33.06M | 0.90× |
| 2022-10-01 | $271.08M | $288.37M | $34.36M | (m) | $132.19M | $76.95M | $19.07M | $31.30M | 0.94× |
| 2022-07-02 | $277.16M | $198.87M | $41.00M | (m) | $143.02M | $69.08M | $25.73M | $22.55M | 1.39× |
| 2022-04-02 | $245.40M | $171.52M | $27.37M | (m) | $119.29M | $64.69M | $22.50M | $20.29M | 1.43× |
| 2021-12-31 | $263.10M | $180.86M | $43.93M | (m) | $124.96M | $61.69M | $16.91M | $18.04M | 1.45× |
| 2021-10-02 | $246.08M | $160.71M | $80.92M | (m) | $105.44M | $36.56M | $10.90M | $15.00M | 1.53× |
| 2021-07-03 | $290.06M | $158.19M | $136.06M | (m) | $102.03M | $34.02M | $9.88M | $15.00M | 1.83× |
| 2021-04-03 | $270.72M | $149.03M | $124.25M | (m) | $89.47M | $39.81M | $10.28M | $15.00M | 1.82× |
| 2020-12-31 | $211.79M | $122.59M | $86.84M | (m) | $88.28M | $29.12M | $4.42M | $15.00M | 1.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.